

Maiwenn J Al

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2280906/publications.pdf>

Version: 2024-02-01

74
papers

3,143
citations

186265
28
h-index

161849
54
g-index

76
all docs

76
docs citations

76
times ranked

4581
citing authors

#	ARTICLE	IF	CITATIONS
1	Model-based cost-effectiveness analyses comparing combinations of urate lowering therapy and anti-inflammatory treatment in gout patients. PLoS ONE, 2022, 17, e0261940.	2.5	6
2	Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate Cancer. Drugs - Real World Outcomes, 2022, , 1.	1.6	0
3	Home Telemonitoring and a Diagnostic Algorithm in the Management of Heart Failure in the Netherlands: Cost-effectiveness Analysis. JMIR Cardio, 2022, 6, e31302.	1.7	1
4	Modeling Early Warning Systems: Construction and Validation of a Discrete Event Simulation Model for Heart Failure. Value in Health, 2021, 24, 1435-1445.	0.3	3
5	Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations. European Journal of Health Economics, 2020, 21, 153-164.	2.8	30
6	Impact of hospitalisation on health-related quality of life in patients with chronic heart failure. Health and Quality of Life Outcomes, 2020, 18, 262.	2.4	14
7	Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges. Frontiers in Public Health, 2020, 8, 612410.	2.7	9
8	Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis. Health Technology Assessment, 2020, 24, 1-220.	2.8	12
9	Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia. Applied Health Economics and Health Policy, 2019, 17, 883-893.	2.1	15
10	TECH-VER: A Verification Checklist to Reduce Errors in Models and Improve Their Credibility. Pharmacoeconomics, 2019, 37, 1391-1408.	3.3	33
11	<p><p>First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis</p><p>. OncoTargets and Therapy, 2019, Volume 12, 1413-1421.	2.0	51
12	Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2019, 37, 141-153.	3.3	8
13	The increasing importance of a continence nurse specialist to improve outcomes and save costs of urinary incontinence care: an analysis of future policy scenarios. BMC Family Practice, 2018, 19, 31.	2.9	9
14	Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2018, 36, 145-159.	3.3	10
15	Early warning systems for the management of chronic heart failure: a systematic literature review of cost-effectiveness models. Expert Review of Pharmacoeconomics and Outcomes Research, 2018, 18, 161-175.	1.4	4
16	Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis. PLoS ONE, 2018, 13, e0205013.	2.5	9
17	Research Costs Investigated: A Study Into the Budgets of Dutch Publicly Funded Drug-Related Research. Pharmacoeconomics, 2018, 36, 105-113.	3.3	5
18	Cost Recommendation under Uncertainty in IQWiG's Efficiency Frontier Framework. Medical Decision Making, 2017, 37, 162-172.	2.4	2

#	ARTICLE	IF	CITATIONS
19	Comparison of cardiovascular risk algorithms in patients with <i>vs</i> without rheumatoid arthritis and the role of C-reactive protein in predicting cardiovascular outcomes in rheumatoid arthritis. <i>Rheumatology</i> , 2017, 56, 777-786.	1.9	28
20	A New Statistical Method to Determine the Degree of Validity of Health Economic Model Outcomes against Empirical Data. <i>Value in Health</i> , 2017, 20, 1041-1047.	0.3	10
21	Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2017, 35, 1211-1221.	3.3	21
22	Mix and match. A simulation study on the impact of mixed-treatment comparison methods on health-economic outcomes. <i>PLoS ONE</i> , 2017, 12, e0171292.	2.5	0
23	Faecal immunochemical tests to triage patients with lower abdominal symptoms for suspected colorectal cancer referrals in primary care: a systematic review and cost-effectiveness analysis. <i>Health Technology Assessment</i> , 2017, 21, 1-234.	2.8	59
24	Effects of Achieving Target Measures in Rheumatoid Arthritis on Functional Status, Quality of Life, and Resource Utilization: Analysis of Clinical Practice Data. <i>Arthritis Care and Research</i> , 2016, 68, 308-317.	3.4	27
25	Use of Value of Information in Healthcare Decision Making: Exploring Multiple Perspectives. <i>Pharmacoeconomics</i> , 2016, 34, 315-322.	3.3	19
26	The Missing Stakeholder Group: Why Patients Should be Involved in Health Economic Modelling. <i>Applied Health Economics and Health Policy</i> , 2016, 14, 129-133.	2.1	33
27	Cardiovascular risk factor management in patients with RA compared to matched non-RA patients. <i>Rheumatology</i> , 2016, 55, 809-816.	1.9	21
28	Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene. <i>Pharmacoeconomics</i> , 2016, 34, 23-31.	3.3	2
29	Integrated sensor-augmented pump therapy systems [the MiniMedÂ® Paradigmâ„¢ Veo system and the Vibeâ„¢ and G4Â® PLATINUM CGM (continuous glucose monitoring) system] for managing blood glucose levels in type 1 diabetes: a systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2016, 20, 1-252.	2.8	57
30	Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia in Ukraine. <i>Cancer Management and Research</i> , 2015, 7, 279.	1.9	8
31	Determining the Impact of Modeling Additional Sources of Uncertainty in Value-of-Information Analysis. <i>Value in Health</i> , 2015, 18, 100-109.	0.3	4
32	Viscoelastic point-of-care testing to assist with the diagnosis, management and monitoring of haemostasis: a systematic review and cost-effectiveness analysis. <i>Health Technology Assessment</i> , 2015, 19, 1-228.	2.8	230
33	Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis. <i>Health Technology Assessment</i> , 2014, 18, 1-106.	2.8	74
34	The use of fenestrated and branched endovascular aneurysm repair for juxtarenal and thoracoabdominal aneurysms: a systematic review and cost-effectiveness analysis. <i>Health Technology Assessment</i> , 2014, 18, 1-66.	2.8	25
35	A Choice That Matters?. <i>Pharmacoeconomics</i> , 2013, 31, 719-730.	3.3	5
36	The Role of Value-of-Information Analysis in a Health Care Research Priority Setting. <i>Medical Decision Making</i> , 2013, 33, 472-489.	2.4	7

#	ARTICLE	IF	CITATIONS
37	Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 353-360.e2.	2.9	263
38	Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trial. <i>European Respiratory Journal</i> , 2013, 41, 556-564.	6.7	9
39	Cost-Effectiveness Acceptability Curves Revisited. <i>Pharmacoeconomics</i> , 2013, 31, 93-100.	3.3	28
40	Continuous versus Intermittent Data Collection of Health Care Utilization. <i>Medical Decision Making</i> , 2013, 33, 998-1008.	2.4	26
41	Economic evaluation alongside a single RCT of an integrative psychotherapeutic nursing home programme. <i>BMC Health Services Research</i> , 2013, 13, 370.	2.2	6
42	Comparing Methods of Data Synthesis. <i>Pharmacoeconomics</i> , 2011, 29, 239-250.	3.3	8
43	Developing and Applying a Stochastic Dynamic Population Model for Chronic Obstructive Pulmonary Disease. <i>Value in Health</i> , 2011, 14, 1039-1047.	0.3	30
44	Inverse probability weighting to control for censoring in a post hoc analysis of quality-adjusted survival data from a clinical trial of temsirolimus for renal cell carcinoma. <i>Journal of Medical Economics</i> , 2011, 14, 245-252.	2.1	2
45	Association between lung function and exacerbation frequency in patients with COPD. <i>International Journal of COPD</i> , 2010, 5, 435.	2.3	79
46	Cost-consequence analysis of remifentanyl-based analgo-sedation vs. conventional analgesia and sedation for patients on mechanical ventilation in the Netherlands. <i>Critical Care</i> , 2010, 14, R195.	5.8	31
47	The cost utility of solifenacin in the treatment of overactive bladder. <i>International Urology and Nephrology</i> , 2009, 41, 293-298.	1.4	12
48	The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report. <i>Value in Health</i> , 2009, 12, 1086-1099.	0.3	69
49	Conclusion on cost-effectiveness of rotavirus vaccination highly dependent on assumptions. <i>Vaccine</i> , 2009, 27, 2531-2532.	3.8	5
50	Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme. <i>Cancer</i> , 2008, 112, 1337-1344.	4.1	44
51	Uncertainty in Decision-Making: Value of Additional Information in the Cost-Effectiveness of Lifestyle Intervention in Overweight and Obese People. <i>Value in Health</i> , 2008, 11, 424-434.	0.3	14
52	Costs and Effects of Various Analgesic Treatments for Patients with Rheumatoid Arthritis and Osteoarthritis in The Netherlands. <i>Value in Health</i> , 2008, 11, 589-599.	0.3	15
53	Economic Valuation of Informal Care: Conjoint Analysis Applied in a Heterogeneous Population of Informal Caregivers. <i>Value in Health</i> , 2008, 11, 1041-1050.	0.3	33
54	Expected Value of Perfect Information: An Empirical Example of Reducing Decision Uncertainty by Conducting Additional Research. <i>Value in Health</i> , 2008, 11, 1070-1080.	0.3	52

#	ARTICLE	IF	CITATIONS
55	The cost-utility of rotavirus vaccination with Rotarix [®] , [®] (RIX4414) in the Netherlands. <i>Vaccine</i> , 2008, 26, 1118-1127.	3.8	69
56	Review of A Large Clinical Series: A Microcosting Study of Intensive Care Unit Stay in the Netherlands. <i>Journal of Intensive Care Medicine</i> , 2008, 23, 250-257.	2.8	38
57	Cost-utility of brief psychological treatment for depression and anxiety. <i>British Journal of Psychiatry</i> , 2006, 188, 323-329.	2.8	54
58	Economic valuation of informal care: The conjoint measurement method applied to informal caregiving. <i>Social Science and Medicine</i> , 2005, 61, 1342-1355.	3.8	63
59	The analysis of incomplete cost data due to dropout. <i>Health Economics (United Kingdom)</i> , 2005, 14, 763-776.	1.7	88
60	Optimal allocation of resources over health care programmes: dealing with decreasing marginal utility and uncertainty. <i>Health Economics (United Kingdom)</i> , 2005, 14, 655-667.	1.7	31
61	Portfolio Theory and Cost-Effectiveness Analysis: A Further Discussion. <i>Value in Health</i> , 2004, 7, 595-601.	0.3	6
62	A Risk-Adjusted Approach to Comparing the Return on Investment in Health Care Programs. <i>International Journal of Health Care Finance and Economics</i> , 2004, 4, 199-210.	1.2	8
63	Decision makers' views on health care objectives and budget constraints: results from a pilot study. <i>Health Policy</i> , 2004, 70, 33-48.	3.0	34
64	Portfolio theory and the alternative decision rule of cost-effectiveness analysis: theoretical and practical considerations. <i>Social Science and Medicine</i> , 2004, 58, 1853-1855.	3.8	10
65	Revisiting the decision rule of cost-effectiveness analysis under certainty and uncertainty. <i>Social Science and Medicine</i> , 2003, 57, 969-974.	3.8	26
66	Optimizing a portfolio of health care programs in the presence of uncertainty and constrained resources. <i>Social Science and Medicine</i> , 2003, 57, 2207-2215.	3.8	45
67	Methods to Analyse Cost Data of Patients Who Withdraw in a Clinical Trial Setting. <i>Pharmacoeconomics</i> , 2003, 21, 1103-1112.	3.3	54
68	Healthcare Resource Utilisation and Costs of Treating NSAID-Associated Gastrointestinal Toxicity. <i>Pharmacoeconomics</i> , 2001, 19, 17-32.	3.3	34
69	A Bayesian approach to economic analyses of clinical trials: the case of stenting versus balloon angioplasty. <i>Health Economics (United Kingdom)</i> , 2000, 9, 599-609.	1.7	31
70	Sample size calculation in economic evaluations. , 1998, 7, 327-335.		47
71	Technology Assessment of the Dutch Lung Transplantation Program. <i>International Journal of Technology Assessment in Health Care</i> , 1998, 14, 344-356.	0.5	37
72	Cost-effectiveness of Lung Transplantation in the Netherlands. <i>Chest</i> , 1998, 113, 124-130.	0.8	52

#	ARTICLE	IF	CITATIONS
73	The Cost Effectiveness of Diclofenac Plus Misoprostol Compared with Diclofenac Monotherapy in Patients with Rheumatoid Arthritis. <i>Pharmacoeconomics</i> , 1996, 10, 141-151.	3.3	13
74	Costs, effects and C/E-ratios alongside a clinical trial. <i>Health Economics (United Kingdom)</i> , 1994, 3, 309-319.	1.7	825